Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Rare cases of occlusive retinal vasculitis have occurred with intravitreal therapies, ...

Ankylosing spondylitis is a seronegative arthropathy which typically involves sacroiliac joints. We described a patient of ankylosing spondylitis with bilateral occlusive retinal vasculitis. A 29-year ...

Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...

Scleritis is the most common ocular manifestation of relapsing polychondritis; in one study, this sign was present in 51 out of 117 patients, and was the presenting feature in 6 patients. [19] ...

Ocular manifestations are common among patients with all types of antineutrophil cytoplasmic antibody-associated vasculitis, and machine learning-based predictive models offer potential for early ...

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis. A study published in ...

– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...

What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...

In July, we reported on cases of unexplained ocular inflammation associated with pegcetacoplan (Syfovre), a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Systemic hypertension is a common complication of systemic vasculitis. Signs of hypertensive retinopathy and choroidopathy will vary, depending on the mode of onset and the severity of hypertension.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...